Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 55Lung Neoplasms 30Ovarian Neoplasms 13Triple Negative Breast Neoplasms 12Small Cell Lung Carcinoma 12Neoplasms 11Neoplasm Metastasis 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Breast Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Colorectal Neoplasms 6Carcinoma 5Adenocarcinoma of Lung 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Oropharyngeal Neoplasms 3Neoplasms by Site 3Mesothelioma 3Lung Diseases 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thoracic Neoplasms 2Sarcoma 2Respiratory Tract Neoplasms 2

Interventions

sintilimab 1pembrolizumab 1osimertinib 1encorafenib 1binimetinib 1Specimen Handling 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × Carboplatin × 30 days × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡